News
TAK
13.03
-0.31%
-0.04
Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Neurocrine Biosciences, Inc. Achieved positive results from its phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with major depressive disorder. The drug may offer several advantages over existing treatment options. The global Major Depressive Disorder treatment market is expected to reach $14.96 billion by 2032. Neurocrine has already received FDA approval for a drug for Huntington's Disease. The company has several catalysts to look forward to.
Seeking Alpha · 1d ago
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Annual Meeting of the American Society of Clinical Oncology will be held in Chicago. The oral presentations will cover a range of topics including targeted therapies and immunologic therapies for various types of cancer. The plenary session will feature presentations on esophageal cancer, melanoma and lung cancer.
Seeking Alpha · 1d ago
Takeda said to have left industry trade group BIO
Japanese drugmaker Takeda said to have left industry trade group BIO. The Biotechnology Innovation Organization claims to be the world's largest biotech trade association. Pfizer's exit from the group last year followed a similar move from the pharma industry's top lobbying group.
Seeking Alpha · 1d ago
All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
NASDAQ · 1d ago
Polaris International Equity Composite Q1 2024 Commentary
Global equity markets enjoyed consecutive months of gains, with the MSCI EAFE Index returning 5.93% for the quarter. The Polaris International Equity Composite returned 3.78% (net of fees), lagging the benchmark. The law of supply and demand played out in copper market prices.
Seeking Alpha · 1d ago
Polaris Global Equity Composite Q1 2024 Commentary
Global equity markets enjoyed consecutive months of gains, with the MSCI World Index returning 9.01% for the quarter. The Polaris Global Equity Composite returned 6.19% (net of fees), lagging the benchmark. Global portfolio had absolute positive gains across all sectors, led by financials, industrials and consumer discretionary holdings.
Seeking Alpha · 1d ago
New Strong Buy Stocks for April 25th
NASDAQ · 1d ago
Best Income Stocks to Buy for April 25th
NASDAQ · 1d ago
Neurocrine succeeds in mid-stage trial for Takeda-partnered depression drug
Neurocrine Biosciences, Inc. Succeeds in mid-stage trial for Takeda-partnered depression drug. The drug was developed in partnership with the Japanese company. The study drug was well tolerated in adults with major depressive disorder, the company says.
Seeking Alpha · 3d ago
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
Neurocrine Biosciences revealed topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with major depressive disorder. Neurocrine and Takeda have entered into a strategic collaboration to develop and commercialize compounds in psychiatry. The company's value largely depends on Ingrezza revenue.
Benzinga · 3d ago
NEUROCRINE BIOSCIENCES INC: SAVITRI STUDY MET KEY SECONDARY ENDPOINTS, INCLUDING STATISTICALLY SIGNIFICANT REDUCTION IN MADRS SCORE AT DAY 56
Reuters · 3d ago
NEUROCRINE BIOSCIENCES INC - REPORTS POSITIVE PHASE 2 DATA FOR NBI-1065845 IN ADULTS WITH MAJOR DEPRESSIVE DISORDER
Reuters · 3d ago
NEUROCRINE BIOSCIENCES INC: NBI-1065845 WAS GENERALLY WELL-TOLERATED
Reuters · 3d ago
NEUROCRINE BIOSCIENCES INC: SAVITRI STUDY MET PRIMARY ENDPOINT
Reuters · 3d ago
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
SAVITRI™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score at Day 28 Met Key Secondary Endpoints, Including Statistically significant reduction in MADRS score at Day 56 NBI-1065845 was generally well tolerated. Neurocrine Biosciences announced positive topline data for its Phase 2 SAVITRI study. The study assessed the efficacy and safety of nBI- 1065845 in adult subjects with major depressive disorder.
PR Newswire · 3d ago
Weekly Report: what happened at TAK last week (0415-0419)?
Weekly Report · 4d ago
Takeda, Astellas, Sumitomo Mitsui Banking To Form JV For Incubation Of Early Drug Discovery Programs
NASDAQ · 4d ago
TAKEDA, ASTELLAS AND SUMITOMO MITSUI BANKING ANNOUNCE MASTER AGREEMENT TO ESTABLISH JOINT VENTURE COMPANY FOR INCUBATION OF EARLY DRUG DISCOVERY PROGRAMS
Reuters · 4d ago
TAKEDA PHARMS USA'S ENTYVIO GETS FDA APPROVAL - WEBSITE
Reuters · 04/19 19:22
Health Care Sector Update for 04/19/2024: SNY, SYRE, TAK, XLV, IBB
NASDAQ · 04/19 13:12
More
Webull provides a variety of real-time TAK stock news. You can receive the latest news about Takeda Pharm through multiple platforms. This information may help you make smarter investment decisions.
About TAK
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.